Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies

• Published in: Journal of clinical pharmacology Vol. 54; no. 11; pp. 1230 - 1238
• Main Authors: Endres, Christopher J., Salinger, David H., Köck, Kathleen, Gastonguay, Marc R., Martin, David A., Klekotka, Paul, Nirula, Ajay, Gibbs, Megan A.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-11-2014; American College of Clinical Pharmacology; Wiley Subscription Services, Inc
• Subjects: Adult; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; brodalumab; Dermatologic Agents - administration & dosage; Dermatologic Agents - pharmacokinetics; Dermatologic Agents - therapeutic use; Double-Blind Method; Drug Administration Schedule; Humans; interleukin 17 receptor; monoclonal antibody; Population; population pharmacokinetics; Psoriasis; Psoriasis - drug therapy; monoclonal antibody; psoriasis; brodalumab; interleukin 17 receptor; population pharmacokinetics
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/jcph.334

Brodalumab, a human monoclonal IgG2‐antibody, acts as a potent antagonist at the interleukin‐17 receptor A, which is important in the pathogenesis of psoriasis. To characterize the pharmacokinetics of brodalumab and assess the effects of covariates, brodalumab concentrations from Phase 1a and Phase 2 clinical studies in healthy adults and subjects with psoriasis were used to construct a population PK model. The final two‐compartment model with parallel linear and non‐linear elimination pathways fit the data well. The population typical values for PK parameters CL, V, and Vmax were 0.223 L/day, 4.62 L, and 5.40 mg/day with between‐subject‐variability of 69.2, 69.6, and 25.9%CV, respectively. Body weight (BW) was an important covariate on CL (and Q), V (and V2) and Vmax, with estimated effect exponents of 0.598, 0.849, and 1.12, respectively. Based on simulations from the final model, for doses between 140 and 210 mg, AUC was predicted to be greater than two fold higher in subjects weighing less than 75 kg compared to reference subjects. Age and diagnosis had smaller influence on exposure and was not clinically significant. These data suggest that BW is an important covariate explaining some of the variability in population PK observed in human clinical trials with brodalumab.